Details for New Drug Application (NDA): 202020

✉ Email this page to a colleague

NDA 202020 describes RAYOS, which is a drug marketed by Horizon and is included in one NDA. There are two patents protecting this drug and one Paragraph IV challenge. Additional details are available on the RAYOS profile page.

The generic ingredient in RAYOS is prednisone. There are sixteen drug master file entries for this compound. Forty-seven suppliers are listed for this compound. Additional details are available on the prednisone profile page.

Summary for 202020

Tradename:	RAYOS
Applicant:	Horizon
Ingredient:	prednisone
Patents:	2

Medical Subject Heading (MeSH) Categories for 202020

Anti-Inflammatory Agents
Antineoplastic Agents, Hormonal
Glucocorticoids

Profile for product number 001

Active Rx/OTC/Discontinued:	DISCN	Dosage:	TABLET, DELAYED RELEASE;ORAL			Strength	1MG
Approval Date:	Jul 26, 2012	TE:		RLD:	Yes
Patent:	⤷ Get Started Free	Patent Expiration:	Aug 3, 2027	Product Flag?		Substance Flag?		Delist Request?
Patented Use:	TREATMENT OF DISEASES OR CONDITIONS BY THE USE OF A DELAYED-RELEASE 1,2, OR 5MG PREDNISONE TABLET

Profile for product number 002

Active Rx/OTC/Discontinued:	DISCN	Dosage:	TABLET, DELAYED RELEASE;ORAL			Strength	2MG
Approval Date:	Jul 26, 2012	TE:		RLD:	Yes
Patent:	⤷ Get Started Free	Patent Expiration:	Aug 3, 2027	Product Flag?		Substance Flag?		Delist Request?
Patented Use:	TREATMENT OF DISEASES OR CONDITIONS BY THE USE OF A DELAYED-RELEASE 1,2, OR 5MG PREDNISONE TABLET

Profile for product number 003

Active Rx/OTC/Discontinued:	DISCN	Dosage:	TABLET, DELAYED RELEASE;ORAL			Strength	5MG
Approval Date:	Jul 26, 2012	TE:		RLD:	Yes
Patent:	⤷ Get Started Free	Patent Expiration:	Jan 7, 2028	Product Flag?	Y	Substance Flag?		Delist Request?
Patented Use:	TREATMENT OF RHEUMATOLOGIC, ALLERGIC, PULMONARY,GASTROINTESTINAL,DERMATOLOGIC DISEASES OR CONDITIONS BY THE USE OF A DELAYED RELEASE 5MG PREDNISONE TABLET

Expired US Patents for NDA 202020

Subscribe to access the full database, or Get Started Free
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Horizon	RAYOS	prednisone	TABLET, DELAYED RELEASE;ORAL	202020-002	Jul 26, 2012	⤷ Get Started Free	⤷ Get Started Free
Horizon	RAYOS	prednisone	TABLET, DELAYED RELEASE;ORAL	202020-003	Jul 26, 2012	⤷ Get Started Free	⤷ Get Started Free
Horizon	RAYOS	prednisone	TABLET, DELAYED RELEASE;ORAL	202020-002	Jul 26, 2012	⤷ Get Started Free	⤷ Get Started Free
Horizon	RAYOS	prednisone	TABLET, DELAYED RELEASE;ORAL	202020-001	Jul 26, 2012	⤷ Get Started Free	⤷ Get Started Free
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.